What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
V. Craig Jordan focuses on Internal medicine, Tamoxifen, Breast cancer, Estrogen receptor and Antiestrogen.
His study in Internal medicine is interdisciplinary in nature, drawing from both Regulation of gene expression, Endocrinology, Oncology and Transfection.
The Tamoxifen study combines topics in areas such as Aromatase and Pharmacology.
The concepts of his Breast cancer study are interwoven with issues in Uterine cancer, Gynecology, Endometrial cancer and Adjuvant therapy.
His Estrogen receptor study combines topics from a wide range of disciplines, such as Receptor, Transcription factor, Estrogen and Molecular biology.
His research integrates issues of Metabolite, Bone density, Ovariectomized rat and Chemotherapy in his study of Antiestrogen.
His most cited work include:
- The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial (1541 citations)
- Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. (1337 citations)
- Basic Guide to the Mechanisms of Antiestrogen Action (650 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Tamoxifen, Breast cancer, Estrogen receptor and Endocrinology.
His Internal medicine study frequently intersects with other fields, such as Oncology.
His Tamoxifen research includes themes of Aromatase, Chemotherapy and Pharmacology.
His Breast cancer research incorporates elements of Gynecology, Osteoporosis and Adjuvant therapy.
His Estrogen receptor research is multidisciplinary, incorporating elements of Receptor and Cancer research.
His Endocrinology study combines topics in areas such as Progesterone receptor and Toremifene.
He most often published in these fields:
- Internal medicine (71.39%)
- Tamoxifen (57.75%)
- Breast cancer (52.14%)
What were the highlights of his more recent work (between 2008-2019)?
- Internal medicine (71.39%)
- Breast cancer (52.14%)
- Tamoxifen (57.75%)
In recent papers he was focusing on the following fields of study:
V. Craig Jordan spends much of his time researching Internal medicine, Breast cancer, Tamoxifen, Oncology and Estrogen.
His Internal medicine study often links to related topics such as Endocrinology.
To a larger extent, he studies Cancer with the aim of understanding Breast cancer.
In his work, Bioinformatics is strongly intertwined with Pharmacology, which is a subfield of Tamoxifen.
He has included themes like Apoptosis and Estrogen receptor in his Estrogen study.
His Estrogen receptor research incorporates themes from Receptor and Cancer research.
Between 2008 and 2019, his most popular works were:
- Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer (478 citations)
- The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. (207 citations)
- Early breast cancer (202 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Tamoxifen, Breast cancer, Estrogen receptor, Internal medicine and Oncology are his primary areas of study.
In his research, Hormone replacement therapy, Bioinformatics and Lasofoxifene is intimately related to Pharmacology, which falls under the overarching field of Tamoxifen.
As part of one scientific family, V. Craig Jordan deals mainly with the area of Breast cancer, narrowing it down to issues related to the Estrogen, and often Apoptosis and Molecular biology.
The various areas that V. Craig Jordan examines in his Estrogen receptor study include Cancer research and Targeted therapy.
His study ties his expertise on Endocrinology together with the subject of Internal medicine.
His Selective estrogen receptor modulator research is multidisciplinary, incorporating perspectives in Antiestrogen and Angiogenesis inhibitor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
